Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)
暂无分享，去创建一个
G. Abou-Alfa | R. Kelley | A. El-Khoueiry | T. Meyer | L. Rimassa | A. Cheng | A. Tran | H. Lim | J. Blanc | P. Merle | B. Ryoo | D. Clary | H. Lim | J. Park | J. Park | A. Tran | A. Borgman-Hagey | E. Wang | R. Kelley